Comparison of baseline virologic, molecular, immunologic, and clinical parameters in responsive and nonresponsive MC patients to PIRR and Peg-IFN-α/RBV treatments
| Parameter . | Therapeutic schedules . | |||
|---|---|---|---|---|
| PIRR, n = 22 . | Peg-IFN-α/RBV, n = 15 . | |||
| Responsive, n = 12 . | Nonresponsive, n = 10 . | Responsive, n = 5 . | Nonresponsive, n = 10 . | |
| Virologic | ||||
| HCV RNA, IU/mL | 766 123 ± 372 823 | 1 346 772 ± 641 080 | 1 201 305 ± 660 340 | 908 413 ± 506 401 |
| HCV genotype, n (%) | ||||
| 1 | 5 (41.7) | 4 (40) | 2 (40) | 5 (50) |
| 2 | 7 (58.3) | 6 (60) | 3 (60) | 5 (50) |
| Molecular, n (%) | ||||
| B-cell clonal expansion | 12 (100) | 10 (100) | 3 (60) | 10 (100) |
| Monoclonal | 1 (8.3) | 9 (90)* | 0 | 6 (60)* |
| Oligoclonal | 11(91.7) | 1 (10)* | 3 (60) | 4 (40) |
| Immunologic | ||||
| Cryocrit, % | 6.3 ± 2.1 | 5.75 ± 2.4 | 4.1 ± 1.7 | 5.8 ± 2.1 |
| Cryoglobulin type, n (%) | ||||
| II | 11 (91.7) | 9 (90) | 3 (60) | 9 (90) |
| III | 1 (8.3) | 1 (10) | 2 (40) | 1 (10) |
| C4 complement fraction, mg/dL | 5.4 ± 3.6 | 4.7 ± 2.15 | 3.9 ± 0.7 | 4.5 ± 1.1 |
| IgM levels, mg/L | 4589 ± 2359 | 3785 ± 2986 | 4800 ± 1220 | 5010 ± 2060 |
| Rheumatoid factor, IU/mL | 428.4 ± 111.3 | 402 ± 165.8 | 505 ± 260 | 460 ± 307 |
| Liver histology | ||||
| Bridging fibrosis/cirrhosis, n (%) | 0 | 2 (20) | 0 | 1 (10) |
| Peripheral neuropathy, n (%) | 3 (25) | 3 (30) | 1 (20) | 2 (20) |
| Nephropathy, n (%) | 4 (33.3) | 1 (10) | 2 (40) | 2 (20) |
| Parameter . | Therapeutic schedules . | |||
|---|---|---|---|---|
| PIRR, n = 22 . | Peg-IFN-α/RBV, n = 15 . | |||
| Responsive, n = 12 . | Nonresponsive, n = 10 . | Responsive, n = 5 . | Nonresponsive, n = 10 . | |
| Virologic | ||||
| HCV RNA, IU/mL | 766 123 ± 372 823 | 1 346 772 ± 641 080 | 1 201 305 ± 660 340 | 908 413 ± 506 401 |
| HCV genotype, n (%) | ||||
| 1 | 5 (41.7) | 4 (40) | 2 (40) | 5 (50) |
| 2 | 7 (58.3) | 6 (60) | 3 (60) | 5 (50) |
| Molecular, n (%) | ||||
| B-cell clonal expansion | 12 (100) | 10 (100) | 3 (60) | 10 (100) |
| Monoclonal | 1 (8.3) | 9 (90)* | 0 | 6 (60)* |
| Oligoclonal | 11(91.7) | 1 (10)* | 3 (60) | 4 (40) |
| Immunologic | ||||
| Cryocrit, % | 6.3 ± 2.1 | 5.75 ± 2.4 | 4.1 ± 1.7 | 5.8 ± 2.1 |
| Cryoglobulin type, n (%) | ||||
| II | 11 (91.7) | 9 (90) | 3 (60) | 9 (90) |
| III | 1 (8.3) | 1 (10) | 2 (40) | 1 (10) |
| C4 complement fraction, mg/dL | 5.4 ± 3.6 | 4.7 ± 2.15 | 3.9 ± 0.7 | 4.5 ± 1.1 |
| IgM levels, mg/L | 4589 ± 2359 | 3785 ± 2986 | 4800 ± 1220 | 5010 ± 2060 |
| Rheumatoid factor, IU/mL | 428.4 ± 111.3 | 402 ± 165.8 | 505 ± 260 | 460 ± 307 |
| Liver histology | ||||
| Bridging fibrosis/cirrhosis, n (%) | 0 | 2 (20) | 0 | 1 (10) |
| Peripheral neuropathy, n (%) | 3 (25) | 3 (30) | 1 (20) | 2 (20) |
| Nephropathy, n (%) | 4 (33.3) | 1 (10) | 2 (40) | 2 (20) |
P < .05.